BioGenerator-supported startup noted for its ‘promising technology’ to more quickly and affordably bring vaccines to market ST. LOUIS – St. Louis bioscience startup VaxNewMo is developing broader and more affordable vaccines faster […]
Read MoreWe are excited to get to work in our new office. More than just bringing all of BioSTL’s components under one roof, our new headquarters in Cortex Innovation Community will […]
Read MoreST. LOUIS, Aug. 6, 2019 – Bayer has awarded BioSTL, a St. Louis-based non-profit which advances and promotes the region’s growing bioscience, innovation and technology community, a $1.5 million grant […]
Read MoreMediBeacon Enters into $30 Million Investment and Exclusive Commercialization Partnership in Greater China with Huadong Medicine MediBeacon and Huadong Medicine will collaboratively work to reach regulatory approval on MediBeacon’s entire […]
Read MoreBioscience startups can find free resources and support at a renovated building in the Cortex district of St. Louis. BioSTL, a nonprofit organization that has launched 150 St. Louis-based startups […]
Read MoreGrant expands BioGenerator Labs and Commercialization Resources ST. LOUIS – BioGenerator, the investment arm of BioSTL, has won a $750,000 grant from the U.S. Department of Commerce Economic Development Administration […]
Read MoreReadout adds veteran executive leadership to its management team ST. LOUIS – Readout, an early-stage digital health company, announced completion of its initial funding round, led by BioGenerator, the investment […]
Read MoreAdarza BioSystems to reveal ZIVA platform at AAI 2019: a fully automated protein multiplex detection system ST. LOUIS (May 2, 2019) — Biotech startup Adarza Biosystems, Inc. announced today that […]
Read MorePress release: https://canopybiosciences.com/news/canopy-biosciences-acquires-zellkraftwerk-gmbh/ Acquisition gives St. Louis-based Canopy an international reach Article by David Nicklaus Expanding internationally, being backed by a prominent private equity firm and tripling in size […]
Read MoreIndalo Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead Antifibrotic Drug Candidate IDL-2965 – Oral integrin antagonist inhibits multiple processes of pathologic fibrosis – Indalo to present at […]
Read More